Navigation Links
Pro-Dex, Inc. Announces Fiscal 2013 Fourth Quarter And Full-Year Results
Date:9/25/2013

IRVINE, Calif., Sept. 25, 2013 /PRNewswire/ -- PRO-DEX, INC. (NasdaqCM: PDEX) today announced financial results for its fiscal 2013 fourth quarter and full-year ended June 30, 2013.

(Logo: http://photos.prnewswire.com/prnh/20111025/LA93174LOGO-c)

Quarter Ended June 30, 2013Sales for the quarter ended June 30, 2013 decreased 26% to $2.7 million from $3.7 million for the corresponding quarter in 2012.  This decrease was due primarily to the previously disclosed reductions in purchases by the Company's former largest customer and to a deferral in the timing of product orders from the Company's current largest powered surgical instrument customer, both of which were partially offset by increases in surgical instrument sales to other customers. 

Gross profit for the quarter ended June 30, 2013 decreased to $565,000, compared to gross profit of $858,000 for the year-ago period, primarily as a result of the sales volume decrease between periods and the accrual in 2013 of anticipated losses from the development portion of certain contracts.  Gross profit as a percentage of sales was 21% for the quarter ended June 30, 2013, as compared to 23% for the corresponding quarter in 2012.  This decrease was due primarily to the effects of the accrual for estimated contract losses and to unfavorable variances consistent with the lower sales and manufacturing volume, partially offset by the effects of improved cost performance and lower warranty costs in 2013, relative to 2012.Operating expenses (which include selling, general and administrative, and research and development expenses) for the quarter ended June 30, 2013 decreased 24% to $1.3 million from $1.7 million in the prior year's corresponding quarter.  Included in operating expenses for the quarter ended June 30, 2013 were severance costs amounting to $173,000, as compared to $36,000 of such costs in t
'/>"/>

SOURCE Pro-Dex, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Pro-Dex, Inc. Appoints Michael J. Berthelot Chief Executive Officer
2. Pro-Dex, Inc. Announces Fiscal 2012 Third Quarter Financial Results Conference Call and Webcast
3. Pro-Dex, Inc. Announces Fiscal Third Quarter and Nine Month Results
4. Pro-Dex, Inc. Announces Update Conference Call and Webcast
5. Pro-Dex, Inc. Announces Fiscal 2012 Fourth Quarter and Full-Year Financial Results Conference Call and Webcast
6. Pro-Dex, Inc. Announces Fiscal 2012 Fourth Quarter And Full-Year Results
7. Pro-Dex, Inc. Announces Fiscal 2013 First Quarter Results
8. Pro-Dex, Inc. Announces Fiscal Second Quarter And Six-Month Results
9. Pro-Dex, Inc. And AO Partners Group Jointly Announce Voting Results
10. Pro-Dex, Inc. Appoints Harold A. Hurwitz Chief Executive Officer
11. Pro-Dex, Inc. Appoints Richard Van Kirk Chief Operating Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... , July 22, 2014  Vernalis plc (LSE: ... of proof-of-concept (POC) for CCP-08, the third programme ... cough cold collaboration. Under this collaboration, POC requires ... successful human pilot comparative study against an immediate ... POC, Vernalis will make a milestone payment to ...
(Date:7/21/2014)... , July 21, 2014 McCord ... patent (U.S. Patent No. 8,796,315). This patent describes ... wound healing.  According to the inventor, Dr. McCord, ... who require wound healing, a composition of an ... derived from umbilical cord blood, such that the ...
(Date:7/21/2014)... , July 21, 2014  EHE International, the recognized ... a nationwide physician network, today announced that Dignity Health ... NV has been named an EHE-certified preventive ... Las Vegas region now have greater ... maintain their health. "EHE is proud ...
Breaking Medicine Technology:Third Product in Vernalis' Cough Cold Pipeline (CCP-08) Achieves Proof-of-Concept 2Third Product in Vernalis' Cough Cold Pipeline (CCP-08) Achieves Proof-of-Concept 3US Patent Office Grants McCord Research Endothelial Cell Treatment Patent 2EHE International Certifies Dignity Health Medical Group Nevada, LLC as Its Newest Partner 2
... LOS ANGELES & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 17, ... focused on,the discovery and development of novel, ... of AV-412, a novel,next generation oral tyrosine ... mutant and drug-resistant lung cancer tumor,models. The ...
... Decreased Tumor Blood Vessel,Density and Serum PSA ... and TUSTIN, Calif., April 17, 2007,/PRNewswire-FirstCall/ -- ... company developing targeted,monoclonal antibodies for the treatment ... today announced that preclinical data,presented at the ...
Cached Medicine Technology:AVEO Presents Preclinical Efficacy Data on AV-412, a Novel Oral,Tyrosine Kinase Inhibitor of EGFR/HER2 for EGFR Mutant and,Drug-Resistant Lung Cancer 2AVEO Presents Preclinical Efficacy Data on AV-412, a Novel Oral,Tyrosine Kinase Inhibitor of EGFR/HER2 for EGFR Mutant and,Drug-Resistant Lung Cancer 3AVEO Presents Preclinical Efficacy Data on AV-412, a Novel Oral,Tyrosine Kinase Inhibitor of EGFR/HER2 for EGFR Mutant and,Drug-Resistant Lung Cancer 4Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus,Docetaxel Reduces Growth of Both Hormone-Dependent and,Hormone-Independent Prostate Cancer by Up to 94 Percent in,Preclinical Studies 2Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus,Docetaxel Reduces Growth of Both Hormone-Dependent and,Hormone-Independent Prostate Cancer by Up to 94 Percent in,Preclinical Studies 3Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus,Docetaxel Reduces Growth of Both Hormone-Dependent and,Hormone-Independent Prostate Cancer by Up to 94 Percent in,Preclinical Studies 4Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus,Docetaxel Reduces Growth of Both Hormone-Dependent and,Hormone-Independent Prostate Cancer by Up to 94 Percent in,Preclinical Studies 5
(Date:7/22/2014)... Cloud+MD Office 2.0 is a ... medical software and services, designed by experienced healthcare ... “Actionable Information” to help Independent Physician Practices, New ... Services optimize a wide range of business processes ... Noticeable Cost Reductions and Better Patient Care. ...
(Date:7/22/2014)... An Ideal Location , Narconon Arrowhead, ... naturally tranquil and very beautiful Arrowhead State Park, overlooking ... for both a rehabilitative setting, as well as a ... of fireworks. Launched over the waters of the ... in the lake, or from the nearby campgrounds and ...
(Date:7/22/2014)... 22, 2014 MonaVie announces today that ... Advisory Board (SAB). The addition of Macdonald will help ... current product development plans and necessary substantiation for research ... Macdonald has been with the company as its nutrition ... helping formulate MonaVie’s RVL and CORE ...
(Date:7/22/2014)... 22, 2014 Joining Conquer Paralysis Now as ... the next decade is Paralympic silver medalist and quadriplegic Jennifer ... became a quadriplegic from a spinal cord injury in 1998. ... a cure for paralysis. , “People define cure differently,” French ... something else. We have the image in our minds of ...
(Date:7/22/2014)... Beach, Florida (PRWEB) July 22, 2014 ... alcohol treatment center located in Pompano Beach, ... approval from the Joint Commission, an independent not-for-profit ... United States. Accreditation signifies that the quality programs ... Joint Commission standards for safety and performance. Ocean ...
Breaking Medicine News(10 mins):Health News:Cloud-MD Software will soon Receive MU2 Certification 2Health News:Narconon Arrowhead Holds Annual Firework Event 2Health News:Narconon Arrowhead Holds Annual Firework Event 3Health News:MonaVie Adds Nutritionist Mark Macdonald to Its Scientific Advisory Board 2Health News:MonaVie Adds Nutritionist Mark Macdonald to Its Scientific Advisory Board 3Health News:Paralympian Jen French Announced as Conquer Paralysis Now’s First Champion 2Health News:Florida Drug and Alcohol Addiction Treatment Center Receives Joint Commission Seal of Approval 2Health News:Florida Drug and Alcohol Addiction Treatment Center Receives Joint Commission Seal of Approval 3
... an effective vaccine against recurrent kidney cancers.// Kidney cancer ... causes about 12,000 deaths in the United States every ... 50s and 60s. Standard treatment involves removal of all ... however, kidney cancer does not respond well to subsequent ...
... shown that a chemotherapy regimen combining vinorelbine (Navelbine) and ... the treatment of hormone-refractory prostate cancer . Specialists say ... in their disease. , However researchers added ... regimen is planned. From a group of 66 patients ...
... Breast cancer survivors can now get up and ... // older women, reported higher body esteem and ... a new study. ,Researchers compared 40 ... sedentary women, all early-stage breast cancer survivors. Regular ...
... has shown that there may be a link of type ... blood has high amounts of iron.// ,In this ... with no history of diabetes, cardiovascular disease or cancer. 700 ... iron concentration of 109 nanograms/milliliter manifested with diabetes whereas ...
... placing a soft plastic tube or catheter into the ... Patients must undergo training for two weeks and ... from the comfort of their home. Hemodialysis patients can ... attached to a blood-cleaning machine at a dialysis center. ...
... replacement therapy among breast cancer survivors has been // stopped ... or new cancers. ,Swedish researchers embarked on the study ... therefore subject to the same menopausal symptoms as other women. ... five years. After the initial 345 women in the study ...
Cached Medicine News:Health News:A Combination Of Drugs Effective In The Treatment Of Hormone-Refractory Prostate Cancer 2
Open wire loops decrease the chance of interfering with instruments, Designed to retract the eyelid during ophthalmic microsurgery or minor office procedures...
For rotating nucleus during phacoemulsification, Also useful for dislocating the nucleus into the anterior chamber during extracapsular cataract extraction, 45, Blunt, Forked, 9.0mm from end...
... drape has two perforations which ... to various single or bilateral ... Refractive drape has two perforations ... adapts to various single or ...
Angled 45, 9mm from end, Longer design from bend to tip allows for easier placement of viscoelastic to all meridians, Dome shape, extra smooth tip...
Medicine Products: